Brackmann Christoph
Known title: Chief Financial OfficerCIK: 0002048634
Brackmann Christoph's purchase track record
Brackmann Christoph has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/29/2025 | NVCR | $232K | +17.5% | +14.7% | +9.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NVCR | ▼ Sell | Open Market | 6,412 | $85K | 3/4/2026 | View on chart |
| NVCR | ▲ Buy | Grant | 55,137 | $0 | 3/3/2026 | View on chart |
| NVCR | ▼ Sell | Tax Withholding | 7,033 | $86K | 11/4/2025 | View on chart |
| NVCR | ▲ Buy | Open Market | 10,000 | $116K | 7/29/2025 | View on chart |
| NVCR | ▲ Buy | Open Market | 5,000 | $58K | 7/29/2025 | View on chart |
| NVCR | ▲ Buy | Open Market | 5,000 | $58K | 7/29/2025 | View on chart |
| NVCR | ▲ Buy | Grant | 54,975 | $1000K | 3/4/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NovoCure Gains Japan Approval for Optune Pax in Pancreatic Cancer
NovoCure received regulatory approval in Japan for Optune Pax to treat pancreatic cancer. This development is significant because it expands the potential market for the company's device. Analyst notes suggest this approval may shift the investment thesis by highlighting the firm's cash generation capabilities.
NovoCure Gains Japan Approval for Optune Pax in Pancreatic Cancer. NovoCure received regulatory approval in Japan for Optune Pax to treat pancreatic cancer. This development is significant because it expands the potential market for the company's device. Analyst notes suggest this approval may shift the investment thesis by highlighting the firm's cash generation capabilities.